PharmAla (MDXXF) Biotech has executed an agreement with Ostfold Hospital Trust of Norway. The sales agreement contains both financial and data-sharing provisions. PharmAla will seek to ship its LaNeo MDMA Clinical Research Materials to Ostfold Hospital Trust at the earliest opportunity, subject to customary regulatory approvals.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXXF:
- PharmAla Biotech Posts Rising Deposits as LaNeo MDMA Demand Builds and Australian Trial Plans Advance
- PharmAla reports FY25 customer deposits C$276,000 vs. C$209,000 last year
- PharmAla reports Q1 customer deposits C$433,000 vs. C$276,000 last quarter
- Psychedelic: Clearmind completes second cohort enrollment for CMND-100 trial
- PharmAla Biotech Contracts UK CDMO for ALA-002 Manufacturing